ARWR PE Ratio & Valuation, Is ARWR Overvalued

Historical Valuation

Arrowhead Pharmaceuticals Inc (ARWR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 31.60 is considered Overvalued compared with the five-year average of -8.35. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between 26.12 to 72.53 according to relative valuation method. Compared to the current price of 74.95 USD , Arrowhead Pharmaceuticals Inc By Overvalued By 3.34%.

Relative Value

Fair Zone

26.12-72.53

Current Price：74.95

3.34%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Arrowhead Pharmaceuticals Inc (ARWR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Arrowhead Pharmaceuticals Inc (ARWR) has a current Price-to-Book (P/B) ratio of 17.33. Compared to its 3-year average P/B ratio of 13.10, the current P/B ratio is approximately 32.31% higher. Relative to its 5-year average P/B ratio of 12.63, the current P/B ratio is about 37.20% higher. Arrowhead Pharmaceuticals Inc (ARWR) has a Forward Free Cash Flow (FCF) yield of approximately -0.48%. Compared to its 3-year average FCF yield of -10.23%, the current FCF yield is approximately -95.33% lower. Relative to its 5-year average FCF yield of -6.88%, the current FCF yield is about -93.05% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ARWR competitors is 10.81, providing a benchmark for relative valuation. Arrowhead Pharmaceuticals Inc Corp (ARWR.O) exhibits a P/S ratio of 31.60, which is 192.25% above the industry average. Given its robust revenue growth of -86.41%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ARWR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ARWR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ARWR currently overvalued or undervalued?

Arrowhead Pharmaceuticals Inc (ARWR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 31.60 is considered Overvalued compared with the five-year average of -8.35. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between 26.12 to 72.53 according to relative valuation method. Compared to the current price of 74.95 USD, Arrowhead Pharmaceuticals Inc is Overvalued By 3.34%.

What is Arrowhead Pharmaceuticals Inc (ARWR) fair value?

ARWR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between 26.12 to 72.53 according to relative valuation method.

How does ARWR's valuation metrics compare to the industry average?

The average P/S ratio for ARWR's competitors is 10.81, providing a benchmark for relative valuation. Arrowhead Pharmaceuticals Inc Corp (ARWR) exhibits a P/S ratio of 31.60, which is 192.25% above the industry average. Given its robust revenue growth of -86.41%, this premium appears unsustainable.

What is the current P/B ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of May 25 2026?

As of May 25 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a P/B ratio of 17.33. This indicates that the market values ARWR at 17.33 times its book value.

What is the current FCF Yield for Arrowhead Pharmaceuticals Inc (ARWR) as of May 25 2026?

As of May 25 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a FCF Yield of -0.48%. This means that for every dollar of Arrowhead Pharmaceuticals Inc's market capitalization, the company generates -0.48 cents in free cash flow.

What is the current Forward P/E ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of May 25 2026?

As of May 25 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a Forward P/E ratio of 111.11. This means the market is willing to pay $111.11 for every dollar of Arrowhead Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of May 25 2026?

As of May 25 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a Forward P/S ratio of 31.60. This means the market is valuing ARWR at $31.60 for every dollar of expected revenue over the next 12 months.

ARWR Valuation